GlucoTrack, Inc. (NASDAQ:GCTK)
| Market Cap | 1.45M-98.1% |
| Revenue (ttm) | 0 |
| Net Income | -15.95M+40.4% |
| EPS | -19.98+86.6% |
| Shares Out | 798.14K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,023,386 |
| Open | 2.32 |
| Previous Close | 2.58 |
| Day's Range | 1.78 - 2.36 |
| 52-Week Range | 1.77 - 136.35 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About GCTK
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
$GCTK stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GCTK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GCTK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GCTK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GCTK Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GCTK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GCTK from public contracts
Source: USAspending.gov
GCTK Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GCTK’s recent data — informational, not investment advice